FDA Approves Hycor Biomedical Test
- Share via
Hycor Biomedical Inc., Garden Grove developer of medical diagnostic products, said Tuesday it has received U.S. Food and Drug Administration clearance to sell an autoimmune test designed to identify various forms of vasculitis, an inflammation of blood vessels.
The Anti-MPO p-ANCA ELISA test is designed to indicate which form of vasculitis a patient has. It complements another test that the FDA previously approved, Hycor said.
The company’s stock, which has nearly quadrupled this year, closed Tuesday at $6.50 a share, off 13 cents, in Nasdaq trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
